(MENAFN- GlobeNewsWire - Nasdaq) The Acute Ischemic Stroke pipeline presents opportunities with 25+ drugs in development across various stages, emphasizing innovative treatments like Prourokinase recombinant, RNS60, and AVLX-144. Key players are focusing on novel approaches, collaborations, and advancing through clinical phases with high potential in stroke therapy.

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Acute Ischemic Stroke - Pipeline Insight, 2025" has been added to ResearchAndMarkets's offering.

The "Acute Ischemic Stroke - Pipeline Insight, 2025" report provides a comprehensive analysis of over 20 companies and 25+ pipeline drugs within the Acute Ischemic Stroke landscape. It delves into pipeline drug profiles across clinical and nonclinical stages, assessing therapeutics by product type, stage, route of administration, and molecule type. Additionally, it highlights inactive pipeline products in this domain.

Acute ischemic stroke (AIS), a severe medical condition, results from a decrease in blood flow to the brain, leading to potential damage and is a chief cause of mortality and disability in the US, affecting approximately 700,000 individuals annually. Often preceded by a transient ischemic attack (TIA), which temporarily decreases brain function, AIS involves blockage of major brain vessels. Mechanical thrombectomy, a treatment method, can be executed up to 24 hours post-symptom onset. Symptoms vary by stroke severity and brain location impacted. Primary symptoms include sudden hemiparesis, monoparesis, visual impairments, and more. Strokes can be triggered by arterial blockages due to atheroma buildup, dislodged atheroma, or blood vessel inflammation or narrowing.

The pathophysiology of AIS is triggered by vessel occlusion, typically leading to brain tissue infarction, and can stem from local vessel blockage or clot embolization. The complexity of ischemic brain damage stems from numerous cellular effects arising from reduced cerebral blood flow (CBF), with extensive research identifying varied pathways in the ischemic cascade.

A structured protocol is crucial for stroke evaluation, beginning with assessing airway, breathing, circulation, and vital signs. Emergency neuroimaging techniques used include CT angiography, MRI, and more, alongside laboratory studies such as CBC and coagulation tests. Therapy for AIS focuses on preserving tissue in areas with decreased, yet viable, perfusion. Recanalization strategies, including recombinant tissue-type plasminogen activators, aim to restore blood flow swiftly to mitigate ischemia's effects. Endovascular procedures and potential neuroprotective agents, such as Alteplase and mechanical thrombectomy, are also considered.

The report outlines a thorough evaluation of the Acute Ischemic Stroke pipeline, detailing disease overview and treatment guidelines. It includes a commercial assessment of pipeline products under development and describes drug mechanisms, clinical studies, approvals, and related product developments like collaborations and acquisitions.

Emerging Drugs

Prourokinase recombinant (Tasly Pharmaceutical): An experimental Phase III thrombolytic drug for AIS, promising efficacy with fewer adverse effects than other thrombolytics.

RNS60 (Revalesio Corporation): In Phase II development, RNS60 enhances mitochondrial function, reduces inflammation, and offers neuroprotection, with orphan and fast-track designations for ALS.

AVLX 144 (Avilex Pharma): A Phase I candidate targeting PSD-95 protein to prevent acute stroke conditions with enhanced neuroprotective properties.

The report also outlines comprehensive drug development activities, including collaborations, acquisitions, and licensing, alongside therapeutic assessments of emerging AIS drugs.

Report Highlights

• Evaluation of challenges and opportunities influencing Acute Ischemic Stroke R&D.
• Focus on novel therapeutic approaches for AIS.

Key Players and Products

• Tasly Pharmaceutical: Prourokinase recombinant
• Revalesio Corporation: RNS60
• Avilex Pharma: AVLX 144
• Other key players include GNT Pharma, Biogen, and others

Key Topics Covered:
Introduction
Executive Summary
Acute Ischemic Stroke: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Acute Ischemic Stroke - Analytical Perspective
Late Stage Products (Phase III)

• Comparative Analysis

Enzastaurin: Denovo BioPharma

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

MDNA55: Medicenna Therapeutics, Inc.

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

Zotiraciclib: Adastra Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

RGN6024: Reglagene, Inc.

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Acute Ischemic Stroke Key Companies
Acute Ischemic Stroke Key Products
Acute Ischemic Stroke - Unmet Needs
Acute Ischemic Stroke - Market Drivers and Barriers
Acute Ischemic Stroke - Future Perspectives and Conclusion
Acute Ischemic Stroke Analyst Views
Acute Ischemic Stroke Key Companies

• Tasly Pharmaceutical
• Revalesio Corporation
• Avilex Pharma
• GNT Pharma
• Biogen
• AptaTargets
• NC Medical Research
• Prolong Pharmaceuticals
• Saillant Therapeutics
• TargED Biopharmaceuticals

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN22102025004107003653ID1110231333